Baxter International Inc. (NYSE:BAX) reported a quarterly sales increase of 8% year over year, exceeding consensus estimates.The company's adjusted earnings per share (EPS) of 44 cents fell short of expectations due to an unfavorable product mix.Baxter's 2026 guidance projects flat sales growth and an EPS range below consensus estimates, contributing to a negative market reaction.Baxter International Inc. (NYSE:BAX) is a key player in the medical products industry, specializing in devices and therapies that ...

Core Insights - Baxter International Inc. shares experienced a 15% decline intra-day following the release of fourth-quarter earnings that fell short of expectations and a weaker-than-anticipated guidance for 2026 [1] Financial Performance - The company reported adjusted EPS of $0.44, which was below analyst estimates of $0.54 [2] - Revenue reached $2.97 billion, surpassing the consensus estimate of $2.84 billion, marking an 8% increase on a reported basis and a 3% operational growth compared to the previous year [2] - Despite the revenue exceeding expectations, concerns regarding profitability negatively impacted investor sentiment [2] Future Guidance - Baxter projected fiscal 2026 adjusted EPS to be in the range of $1.85 to $2.05, significantly lower than the analyst consensus of $2.25 [2] Operational Challenges - President and CEO Andrew Hider acknowledged that while sales growth was achieved across all segments, the fourth-quarter performance did not meet internal expectations, highlighting the company's focus on operational improvements [3] - The company reported a U.S. GAAP net loss from continuing operations of $2.01 per diluted share, which included a $485 million goodwill impairment charge related to its Front Line Care reporting unit and a $330 million valuation allowance on U.S. deferred tax assets [3] Segment Performance - Medical Products & Therapies revenue increased by 6% to $1.39 billion [4] - Healthcare Systems & Technologies revenue rose by 5% to $827 million [4] - Pharmaceuticals revenue grew by 4% to $668 million [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 1-4448 _____________________________________________________________________________________________ Baxter International Inc. Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K ____________________________________ ...

Shares of Baxter International Inc. ( BAX ) were battered following soft Q4 numbers and an ugly FY 2026 guide on Thursday, Feb. 12. Once a stalwart in the Healthcare Equipment industry, the now $9.6 billion market cap stock trades with a single-digit price-to-earnings ratio andFreelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a co ...

Shares of Baxter International Inc. ( BAX ) were battered following soft Q4 numbers and an ugly FY 2026 guide on Thursday, Feb. 12. Once a stalwart in the Healthcare Equipment industry, the now $9.6 billion market cap stock trades with a single-digit price-to-earnings ratio andFreelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a co ...

经济观察网百特国际(BAX.US)股票在2026年2月12日出现显著下跌，主要原因为公司发布的2025年第四 季度业绩及2026财年盈利指引不及市场预期。 股票近期走势 受业绩利空冲击，百特国际股价在2月12日盘中暴跌15.00%，收盘报18.93美元，成交额达3.74亿美元， 换手率3.76%。同日，美股医疗设备板块整体下跌3.59%，反映出行业面临的共同压力。 公司对2026财年的业绩展望加剧了市场悲观情绪。百特国际预计2026年调整后每股收益区间为1.85至 2.05美元，显著低于分析师共识预期。这一指引表明公司面临成本压力或增长动力不足的问题。 财务状况 财报显示，第四季度按美国通用会计准则计算，公司录得持续经营业务每股净亏损2.01美元，其中包括 与前线护理业务相关的4.85亿美元商誉减值费用，以及3.3亿美元的美国递延税资产估值准备金。这些一 次性费用严重影响了当期净利润。 以上内容基于公开资料整理，不构成投资建议。 业绩经营情况 根据公司2026年2月12日公布的财报，2025年第四季度调整后每股收益为0.44美元，远低于分析师普遍 预期。尽管季度营收达到29.7亿美元，超出市场预期，但盈利能力 ...

Baxter reported a fourth-quarter adjusted EPS of 44 cents, below the management guidance of 52-57 cents and the Wall Street estimate of 54 cents. The decrease was driven primarily by an unfavorable product mix.The medical device maker reported sales of $2.974 billion, up 8% year over year on a reported basis and 3% on an operational basis, beating the consensus of $2.824 billion.Management expected fourth-quarter sales growth of approximately 2% on a reported basis and a decline of approximately 2% on an op ...

Key Takeaways BAX posted Q4 EPS of 44 cents, down 24%, missing estimates despite 8% revenue growth.Adjusted gross margin fell 900 bps to 35.5%, with operating income down 16% year over year.BAX sees 2026 sales flat to up 1% and EPS of $1.85-$2.05, below consensus estimates.Baxter International Inc. (BAX) reported fourth-quarter 2025 adjusted earnings per share (EPS) from continuing operations of 44 cents, which missed the Zacks Consensus Estimate of 53 cents by 17%. The bottom line declined 24% from the yea ...

分组1 - Baxter International reported quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.53 per share, and down from $0.58 per share a year ago, representing an earnings surprise of -17.42% [1] - The company posted revenues of $2.97 billion for the quarter, surpassing the Zacks Consensus Estimate by 6.44%, compared to year-ago revenues of $2.75 billion [2] - Baxter shares have increased approximately 16.5% since the beginning of the year, outperforming the S&P 500's gain of 1.4% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.50 on revenues of $2.64 billion, and for the current fiscal year, it is $2.33 on revenues of $11.28 billion [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 33% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Baxter International (NYSE:BAX) Q4 2025 Earnings call February 12, 2026 08:30 AM ET Company ParticipantsAndrew Hider - President and CEODavid Roman - Managing DirectorJoanne Wuensch - Managing Director in the Equity Research DivisionJoel Grade - EVP and CFOKevin Moran - VP and Head of Investor RelationsVijay Kumar - Senior Managing DirectorConference Call ParticipantsDanielle Antalffy - Senior Equity Research AnalystLarry Biegelsen - Managing Director and Senior Medical Device Equity Research AnalystRobbie ...